SonoThera

The page covers gene therapy news about developments influencing modern genetic medicine.

The page lists gene therapy jobs focused on genetic innovation, therapy development, and patient impact.

The page describes how gene therapy is redefining precision medicine through targeted, repeatable, and safer therapeutic approaches.

The page describes Sonothera’s work on gene therapy delivery platforms and clinical progress.

The page describes therapeutic ultrasound for non-invasive, targeted genetic medicine delivery that improves precision and biodistribution.

SonoThera raises an oversubscribed $125 million Series B led by Vida Ventures to advance its microbubble-based ultrasound gene-delivery platform toward clinical trials in DMD. The round includes participation from Big Pharma-affiliated investors and funds development of the approach.

Jun 2026 · Fierce BiotechNews article

SonoThera closed an oversubscribed $125 million Series B financing led by Vida Ventures. The round includes new investors ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka, SymBiosis, UCB Ventures and Vivo Capital, alongside existing investors. Proceeds will advance the company’s Duchenne muscular dystrophy and ADPKD programs toward clinical trials and support development of its RIPPLE and PORE platforms.

Jun 2026 · SonoTheraNews article

SonoThera presents preclinical data at the Muscular Dystrophy Association 2026 conference showing that RIPPLE delivers full-length dystrophin in Duchenne muscular dystrophy models using an ultrasound-mediated, nonviral approach. The company describes the platform as efficient and scalable for full-length dystrophin delivery.

Mar 2026 · SonoTheraNews article

SonoThera launches a $125 million Series B financing at the 44th J.P. Morgan Healthcare Conference to advance multiple genetic medicine programs. The capital supports programs across its ultrasound-mediated nonviral delivery pipeline.

Jan 2026 · SonoTheraNews article